Literature DB >> 29366813

Anatomic mesohepatectomy versus extended hepatectomy for patients with centrally located hepatocellular carcinoma.

Wei Li1, Long Li2, Daniil Minigalin3, Hong Wu4.   

Abstract

BACKGROUND: Both mesohepatectomy (MH) and extended hepatectomy (EH) can be performed for centrally located hepatocellular carcinoma (HCC). In this study, the long-term prognosis of these surgical approaches was assessed in patients with HCC.
METHODS: A retrospective review was undertaken of 171 HCC patients who underwent anatomic hepatectomy for centrally located HCC between January 2005 and January 2016 in West China Hospital, Sichuan University. The impact of the surgical methods on prognosis was assessed for these patients by multivariable regression analysis. In addition, the patients in the MH group were matched in a 1:2 ratio with EH controls.
RESULTS: In non-adjusted models, patients in the MH group had similar overall survival (OS, p = 0.066) and disease free survival (DFS, p = 0.654) compared to EH patients. After adjusting for all identified confounders, MH patients showed better OS in comparison with patients in the EH group (p = 0.001), while the DFS was similar. In the propensity score-matched (PSM) subset, patients in MH group had better OS (p = 0.033) but similar DFS (p = 0.328) compared to patients in the EH group.
CONCLUSION: Anatomic MH can be recommended as a reasonable surgical option in selected patients with centrally located HCC.
Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29366813     DOI: 10.1016/j.hpb.2017.11.012

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  6 in total

1.  Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis.

Authors:  Wei Li; Jun Han; Guowei Xie; Yang Xiao; Ke Sun; Kefei Yuan; Hong Wu
Journal:  Surg Endosc       Date:  2018-11-29       Impact factor: 4.584

2.  Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma.

Authors:  Wei Li; Lin Xu; Jun Han; Kefei Yuan; Hong Wu
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

3.  Early versus late recurrence of centrally located hepatocellular carcinoma after mesohepatectomy: A cohort study based on the STROBE guidelines.

Authors:  Jun Zhao; Wei Li; Jie Mao
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

4.  Integrated tumor stromal features of hepatocellular carcinoma reveals two distinct subtypes with prognostic/predictive significance.

Authors:  Wei Li; Jun Han; Kefei Yuan; Hong Wu
Journal:  Aging (Albany NY)       Date:  2019-07-12       Impact factor: 5.682

5.  A classification based on tumor budding and immune score for patients with hepatocellular carcinoma.

Authors:  Li Wei; Zhang Delin; Yuan Kefei; Wu Hong; Huang Jiwei; Zhang Yange
Journal:  Oncoimmunology       Date:  2019-11-07       Impact factor: 8.110

6.  A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion.

Authors:  Wei Chen; Hao Wang; Tong Li; Te Liu; Wenjing Yang; Anli Jin; Lin Ding; Chunyan Zhang; Baishen Pan; Wei Guo; Beili Wang
Journal:  BMC Med Genomics       Date:  2022-02-24       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.